Bosentan: a dual endothelin receptor antagonist

By Roux Sébastien   Rubin Lewis J  

Expert Opinion on Investigational Drugs, Vol. 11, Iss. 7, 2002-07 ,pp. : 991-1002

Informa Healthcare

Access to resources Recommend Favorite

Bosentan, a dual endothelin receptor antagonist, activates the pregnane X nuclear receptor

By van Giersbergen P.L.M.   Gnerre C.   Treiber A.   Dingemanse J.   Meyer U.A.  

European Journal of Pharmacology, Vol. 450, Iss. 2, 2002-08 ,pp. : 115-121

Elsevier

Access to resources Recommend Favorite

Investigation of the Mutual Pharmacokinetic Interactions Between Bosentan, a Dual Endothelin Receptor Antagonist, and Simvastatin

By Dingemanse J.  

Clinical Pharmacokinetics, Vol. 42, Iss. 3, 2003-01 ,pp. : 293-301

Adis International

Access to resources Recommend Favorite

A Phase II study of bosentan, a dual endothelin receptor antagonist, as monotherapy in patients with stage IV metastatic melanoma

By Kefford Richard   Beith Jane   Hazel Guy   Millward Michael   Trotter James   Wyld David   Kusic Rada   Shreeniwas Revati   Morganti Adele   Ballmer Andrea   Segal Eleonor   Nayler Oliver   Clozel Martine  

Investigational New Drugs, Vol. 25, Iss. 3, 2007-06 ,pp. : 247-252

Springer Publishing Company

Access to resources Recommend Favorite

The endothelin receptor antagonist bosentan [`Tracleer'; Actelion] has been approved in Canada

By  

Inpharma, Vol. 1, Iss. 1318, 2001-01 ,pp. : 22-22

Adis International

Access to resources Recommend Favorite